Russell S Fuhrer, MD

Shifeng S Mao, MD, PhD, is the chair of the AHN Cancer Institute urological oncology team. His practice and research focus on genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, and testicular cancer. He is an Associate Professor Medicine at Drexel University College of Medicine. Dr. Mao is an active researcher and the principal investigator of many clinical trials. He has active collaborations with colleagues from Johns Hopkins Kimmel Cancer Center and Carnegie Mellon University. He is the recipient of American Society of Clinical Oncology (ASCO) Young Investigator Award. He has published many research studies in medical journals and presented his findings at national conferences. His experience in cancer research gives him a unique perspective and insight into the biology of cancer, which enhances his clinical care with patients. Dr. Mao earned his medical degree from Beijing Medical University and his doctorate in medical pathology from University of Tennessee Health Science Center. He completed his residency at New York University School of Medicine and continued his studies through a fellowship at the University of Texas Medical School at Houston/MD Anderson Cancer Center.

Dr. Wagner specializes in the surgical treatment of digestive and complex abdominal tumors, including esophageal, gastric, pancreatic, liver, colorectal, and appendix cancers. He cares for patients with metastatic cancer, including liver and peritoneal metastases, as well as patients with rare tumor types such as sarcoma and neuroendocrine tumors. Dr. Wagner serves as the director of Complex General Surgical Oncology at Allegheny Health Network Cancer Institute. He received his medical degree from Harvard Medical School in Boston, Massachusetts, and completed surgical and pathology residencies at NewYork-Presbyterian Weill Cornell Medical Center in New York, New York. He completed a fellowship in surgical oncology at the University of Pittsburgh Medical Center. Dr. Wagner is certified both by the American Board of Surgery and by the American Board of Pathology, and is a Fellow of the American College of Surgeons and a member of the Society of Surgical Oncology. He prioritizes patient-centered, individualized care planning in his clinical practice, and emphasizes minimally invasive approaches, including robotic surgery whenever possible. Dr. Wagner strives to make innovative treatment options available to patients with complex cancers through translational research and clinical trials.